Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Subscribe To Our Newsletter & Stay Updated